COM902, a novel therapeutic antibody targeting TIGIT augments anti-tumor T cell function in combination with PVRIG or PD-1 pathway blockade.
Hansen K, Kumar S, Logronio K, Whelan S, Qurashi S, Cheng HY, Drake A, Tang M, Wall P, Bernados D, Leung L, Ophir E, Alteber Z, Cojocaru G, Galperin M, Frenkel M, White M, Hunter J, Liang SC, Kotturi MF.
Hansen K, et al. Among authors: logronio k.
Cancer Immunol Immunother. 2021 Dec;70(12):3525-3540. doi: 10.1007/s00262-021-02921-8. Epub 2021 Apr 26.
Cancer Immunol Immunother. 2021.
PMID: 33903974
Free PMC article.